UBS analyst Carter Gould upgraded Incyte (INCY) to Buy while lowering his price target for the shares to $76 from $106. The stock offers an improved risk/reward profile after resetting lower on negative epacadostat Phase 3 data and removal of the drug from analyst models, Gould tells investors in a research note. The focus on epacadostat "obscured an otherwise solid, profitable, and strategically attractive Jakafi franchise," the analyst contends. He believes the base business alone supports $65 per share, even before considering its "compelling strategic attractiveness." Incyte closed yesterday down $1.83 to $66.29. Gould thinks clinical catalysts against low expectations can drive $13-$17 per share of upside over 2018.